These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15841900)

  • 1. Acetylcholinesterase and butyrylcholinesterase--important enzymes of human body.
    Patocka J; Kuca K; Jun D
    Acta Medica (Hradec Kralove); 2004; 47(4):215-28. PubMed ID: 15841900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene-di-N-substituted carbamates.
    Chiou SY; Huang CF; Hwang MT; Lin G
    J Biochem Mol Toxicol; 2009; 23(5):303-8. PubMed ID: 19827033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease].
    Patocka J; Strunecká A; Rípová D
    Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease.
    Geula C; Darvesh S
    Drugs Today (Barc); 2004 Aug; 40(8):711-21. PubMed ID: 15510242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterases and the fine line between poison and remedy.
    Pope CN; Brimijoin S
    Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
    Makhaeva GF; Aksinenko AY; Sokolov VB; Serebryakova OG; Richardson RJ
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5528-30. PubMed ID: 19717305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene.
    Johnson G; Moore SW
    Neurochem Int; 2012 Oct; 61(5):783-97. PubMed ID: 22750491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why acetylcholinesterase reactivators do not work in butyrylcholinesterase.
    Wiesner J; Kríz Z; Kuca K; Jun D; Koca J
    J Enzyme Inhib Med Chem; 2010 Jun; 25(3):318-22. PubMed ID: 19874115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterases, a target of pharmacology and toxicology.
    Pohanka M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):219-29. PubMed ID: 22286807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cholinesterases: structure, role, and inhibition].
    Bosak A; Katalinić M; Kovarik Z
    Arh Hig Rada Toksikol; 2011 Jun; 62(2):175-90. PubMed ID: 21705306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
    Tasker A; Perry EK; Ballard CG
    Expert Rev Neurother; 2005 Jan; 5(1):101-6. PubMed ID: 15853480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.
    Zhan ZJ; Bian HL; Wang JW; Shan WG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1532-4. PubMed ID: 20144867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
    Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of carbamate-modified (-)-N(1)-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors.
    Takahashi J; Hijikuro I; Kihara T; Murugesh MG; Fuse S; Tsumura Y; Akaike A; Niidome T; Takahashi T; Sugimoto H
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1721-3. PubMed ID: 20137941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.
    Das UN
    Med Sci Monit; 2007 Dec; 13(12):RA214-21. PubMed ID: 18049445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
    Lane RM; Potkin SG; Enz A
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.
    Darvesh S; Darvesh KV; McDonald RS; Mataija D; Walsh R; Mothana S; Lockridge O; Martin E
    J Med Chem; 2008 Jul; 51(14):4200-12. PubMed ID: 18570368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate activation of butyrylcholinesterase and substrate inhibition of acetylcholinesterase by 3,3-dimethylbutyl-N-n-butylcarbamate and 2-trimethylsilyl-ethyl-N-n-butylcarbamate.
    Chiou SY; Wu YG; Lin YF; Lin LY; Lin G
    J Biochem Mol Toxicol; 2007; 21(1):24-31. PubMed ID: 17366539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.